FDA Clears Sight Sciences' Next-Gen OMNI Ultra Glaucoma Device
SGHT has more than doubled off its 52-week low of $3.19.
Summary
Sight Sciences received FDA 510(k) clearance for its OMNI Ultra Surgical System, a next-generation implant-free MIGS device for glaucoma. The system is the first cleared for single-pass circumferential canaloplasty, featuring TruSync Plus technology for enhanced control and precision. This expands the company's leadership in interventional glaucoma and builds on the proven OMNI platform, which has been used in over 350,000 procedures. The clearance is a significant regulatory milestone that strengthens the product portfolio and opens a new growth avenue. Commercial launch is planned for Q4 2026, providing a near-term catalyst. The news follows a strong Q1 2026 with double-digit revenue growth and a legal win against Alcon, reinforcing positive momentum.
At the time of this announcement, SGHT was trading at $6.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $306.9M. The 52-week trading range was $3.19 to $9.24. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.